Sage Journals: Discover world-class research

Abstract

Objective:

The objective of this study was to increase recognition of ultra-rapid metabolising status as a cause of treatment-resistant depression and consider management options.

Conclusions:

The incidence of ultra-rapid metabolising status is not rare in patients who fail to report improvement with antidepressant medication. Two broad options are available for identifying ultra-metabolising status. While there are several management options available to the clinician, combination therapy is likely of low utility while there are risks associated with mega-prescribing. As the literature is limited, clinician observations about alternate strategies would be welcomed.

Keywords

ultra-rapid metabolising status genotyping treatment-resistant depression

Get full access to this article

View all access options for this article.

References

Laine

Tybring

Härtter

. Inhibition of cytochrome P450D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 2001; 70: 327–335.

Krause

Diaz

McEachran

Managing rapid metabolizers of antidepressants. Depression Anxiety 1997; 4: 320–327.

De Leon

Armstrong

Cozza

. Clinical guidelines for psychiatrists for the use of pharmacogenetics testing for CYP450 2 D6 and CYP450 2C19. Psychosomatics 2006; 47: 75–85.

Linder

Keck

PE.

Standards of laboratory practice: antidepressant drug monitoring. Clin Chem 1998; 44: 1073–1084.

Parker

Brotchie

Do the old psychostimulant drugs have a role in managing treatment-resistant depression?

Acta Psychiatr Scand 2010; 121: 308–314.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB